To include your compound in the COVID-19 Resource Center, submit it here.

Ultragenyx's rhGUS meets Phase III endpoint

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) said rhGUS (UX003) met the primary endpoint in a Phase III study to treat mucopolysaccharidosis VII (MPS VII; Sly syndrome) by significantly reducing urinary excretion of glycosaminoglycan (GAG) dermatan sulfate

Read the full 340 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE